Epidemiology of cancer associated venous thrombosis, Blood, vol.122, pp.1712-1735, 2013. ,
Cancer associated venous thromboembolism:burden, mechanisms, and management, Thromb Haemost, vol.117, pp.219-249, 2017. ,
Malignancies, prothrombotic mutations, and the risk of venous thrombosis, JAMA. 9 févr, vol.293, issue.6, pp.715-737, 2005. ,
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, vol.100, pp.3484-3492, 2002. ,
Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients, American Heart Journal. 1 déc, vol.114, issue.6, pp.1432-1437, 1987. ,
Frequency, riskfactors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, vol.110, pp.2339-2385, 2007. ,
Epidemiology of cancerassociated venous thrombosis, Blood, vol.122, issue.10, pp.1712-1735, 2013. ,
Tissue Factor regulation by Epidermal Growth Factor Receptor and epithelial-to mesenchymal transitions: Effect on tumor initiation and angiogenesis, Cancer Res, vol.68, pp.10068-76, 2008. ,
Protease-activated receptor-2 is essential for factor VIIa and Xainduced signalling migration, and invasion of breast cells, Cancer Res, vol.66, pp.307-321, 2006. ,
Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of tumor breast cancer cells, Thromb Heamost, vol.100, pp.127-160, 2008. ,
Hypercoagulability and tissue factor geneupregulation in hematologic malignancies, Semin Thromb Hemost, vol.34, pp.204-214, 2008. ,
Interaction of coagulation factors and tumor-associatedmacrophages mediates migration and invasion of gastric cancer, Cancer Sci, vol.102, pp.336-378, 2011. ,
Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand-1 accelerate thrombus formation in vivo, JExp Med, vol.206, pp.1913-1940, 2009. ,
Tissue factor and fibrin in tumor angiogenesis, Semin Thromb Hemost, vol.30, pp.31-44, 2004. ,
Cancer procoagulant (CP) analysis inhuman WM11 malignant melanoma cells in vitro, Thromb Res, vol.124, pp.364-371, 2009. ,
Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis, Proc Natl Acad Sci, vol.109, issue.32, pp.13076-81, 2012. ,
Heparin and lowmolecular-weight heparin : mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety, Chest, vol.119, issue.1, pp.64-94, 2001. ,
Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor : evidence for a difference in antithrombotic action, Br J Haematol, vol.101, pp.638-684, 1998. ,
Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not withtwo low molecular weight heparins, Br J Haematol, vol.107, pp.756-62, 1999. ,
Physiological function of tissue factor pathway inhibitor and interaction with heparins, Haemostasis, vol.30, pp.48-56, 2000. ,
Utilisation des héparines de bas poids moléculaire (HBPM) chez le patient insuffisant rénal en milieu hospitalier, Journal de Pharmacie Clinique. 1 juin, vol.30, issue.2, pp.61-74, 2011. ,
New oral anticoagulants and the cancerpatient, Oncologist, vol.19, pp.82-93, 2014. ,
Dabigatran versus warfarin in thetreatment of acute venous thromboembolism, N Engl J, vol.361, pp.2342-52, 2009. ,
Treatment of acute venous thromboembolismwith dabigatran or warfarin and pooled analysis, vol.129, p.12, 2014. ,
Oral rivaroxaban for symptomaticvenous thromboembolism, N Engl J Med, vol.363, pp.2499-510, 2010. ,
Oral rivaroxaban for the treat-ment of symptomatic pulmonary embolism, N Engl J, vol.366, pp.1287-97, 2012. ,
Oral apixaban for the treatment of acute venousthromboembolism, N Engl J Med, vol.369, pp.799-808, 2013. ,
,
, Edoxaban versus warfarin forthe treatment of symptomatic venous thromboembolism, NEngl J Med, vol.369, pp.1406-1421, 2013.
Hokusai VTE cancer investigators. Edoxaban for thetreatment of cancer-associated venous thromboembolism, NEngl J Med, vol.378, pp.615-639, 2018. ,
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D), J Clin Oncol. 10 juill, vol.36, issue.20, pp.2017-2040, 2018. ,
Direct oral anticoagulant (DOAC) versus low-molecularweight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis, Thromb Res. 2 mars, 2018. ,
Evaluation of US prescription patterns: Are treatment guidelines for cancerassociated venous thromboembolism being followed?, Thromb Res, vol.145, pp.51-54, 2016. ,
Venous thromboembolism prophylaxis and treatment in patients with cancer ,
, ASCO Clinical Practice Guideline Update, J. Clin Oncol, vol.31, pp.2189-2204, 2013.
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, J. Thromb Haemost, vol.11, pp.56-70, 2013. ,
Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma, Leukemia. févr, vol.22, issue.2, pp.414-437, 2008. ,
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial, J Clin Oncol. 10 mars, vol.29, issue.8, pp.986-93, 2011. ,
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study ,
, Haematologica, vol.102, issue.9, pp.1494-501, 2017.
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study, Cancer, vol.104, pp.2822-2831, 2005. ,
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, vol.22, issue.6, pp.85-92, 2011. ,
Venous thromboembolic disease, J Natl Compr Canc Netw, vol.9, issue.07, pp.714-777, 2011. ,
,
, Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update, J Clin Oncol, vol.33, issue.06, pp.654-656, 2014.
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, vol.17, issue.10, pp.452-466, 2016. ,
Antithrombotic therapy for VTE disease. CHEST guidelines and expert panel report, Chest, vol.149, issue.02, pp.315-352, 2016. ,
,
, Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
, Cochrane Database Syst Rev, issue.6, p.6649, 2011.
Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, vol.112, pp.416-438, 2005. ,
Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism, Circulation. 24 juill, vol.126, issue.4, pp.448-54, 2012. ,
,
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer, Am. J. Med, vol.119, issue.12, pp.1062-1072, 2006. ,
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period, Clin. Appl. Thromb. Hemost, vol.12, issue.4, pp.389-396, 2006. ,
Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial, CATCH Investigators, vol.314, pp.677-686, 2015. ,
,
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer, Cochrane Database Syst. Rev, vol.7, p.6650, 2014. ,
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study, J. Thromb. Haemost, vol.13, issue.6, pp.1028-1035, 2015. ,
Atrial fibrillation in cancer patients: Hindsight, insight and foresight, Int J Cardiol. 1 août, vol.240, pp.196-202, 2017. ,
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation, Blood Adv. 13 févr, vol.2, issue.3, pp.200-209, 2018. ,
Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II, Thromb Haemost. Juin, vol.105, issue.6, pp.962-969, 2011. ,
Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer, Oncologist, vol.17, issue.3, pp.419-446, 2012. ,
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study, Thromb Haemost. sept, vol.108, issue.3, pp.493-501, 2012. ,
Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study, J Mal Vasc. mai, vol.39, issue.3, pp.161-169, 2014. ,
Low-molecularweight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study, Thromb Res. Août, vol.144, pp.85-92, 2016. ,
Application des recommandations dans le traitement de la maladie thromboembolique veineuse chez les patients atteints de cancer : étude rétrospective sur 145 cas, Journal des Maladies Vasculaires. 1 mai, vol.38, issue.3, pp.185-92, 2013. ,
Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study, Support Care Cancer, vol.105, issue.8, pp.3369-77, 2016. ,
Management of venous thromboembolism in cancer patients according to guidelines after educative measures, Bull Cancer. mai, vol.105, issue.5, pp.486-92, 2018. ,
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome, Am J Med, vol.122, issue.8, pp.762-769, 2009. ,
Physician and patient perceptions of the route of adminis-tration of venous thromboembolism prophy-laxis: results from an international survey, Thromb Res, vol.129, issue.2, pp.139-184, 2012. ,
French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group, Crit Rev Oncol Hematol, vol.73, issue.1, pp.31-46, 2008. ,
URL : https://hal.archives-ouvertes.fr/ujm-00439710
Effect of syringe size on bruising following subcutaneous heparin injection, Am J Crit Care, vol.5, pp.271-277, 1996. ,
A feasibility study to inform the design of a randomised con-trolled trial to identify the most clinically effective and cost-effective length of anticoagulation with low-molecular-weight heparin in the treatment of cancer-associated thrombosis (ALICAT), Health Technol Assess, vol.19, issue.83, pp.1-93, 2015. ,
Long-term treatment for cancer patients with deep venous thrombosis or pulmonary embolism (LONGHEVA) ,
Réunion de concertation pluridisciplinaire thrombose et cancer : l'expérience nantaise, J Mal Vasc, vol.40, issue.2, 2015. ,